Read our review of some of the biggest FDA-related stories that have hit cardiology in the last month, including news from Viz.ai, Edwards Lifesciences, Abiomed and Medtronic. 

When these malfunctions occur, the FDA explained, it leads to an increased risk of additional interventions.

Joao Cavalcante, MD, director, cardiac MRI and structural CT labs, Minneapolis Heart Institute, discusses the use of cardiac CT imaging to plan and guide structural heart procedures. 

Two late-breaking studies at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) meeting provided positive data for Abbott's MitraClip transcatheter mitral valve repair (TMVR) device and the TriClip for transcatheter tricuspid valve repair (TTVR).

This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.

The company can now update its labeling instructions for the device to include a new 45-day dual anti-platelet therapy treatment option when treating non-valvular atrial fibrillation. 

Rebecca T. Hahn, MD, Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center, discusses some of the trends in the growing use of interventional echocardiographic guidance in transcatheter structural heart procedures.

Atrial secondary mitral regurgitation has been linked to higher in-hospital mortality and hospitalization rates.